F
Ford Motor Company
F has the edge over MED overall, supported by stronger fundamentals and lower modeled downside.
MED
Medifast, Inc.
MED offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
F Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Strong |
F's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
MED Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Strong |
MED's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
F PE Valuation
F has no meaningful PE right now: it lost money over the past year.
MED PE Valuation
MED has no meaningful PE right now: it lost money over the past year.
F Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect F's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
MED Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect MED's losses to shrink, with revenue holding steady.
F Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.78 | — |
| Q3 2026 | -$1.97 | -270% |
| Q2 2026 | -$1.87 | -340% |
| Q1 2026 | -$1.55 | -224% |
| Q4 2025 | -$2.06 | -241% |
| Q3 2025 | $1.16 | +32% |
| Q2 2025 | $0.78 | -19% |
| Q1 2025 | $1.25 | +29% |
| Q4 2024 | $1.46 | +35% |
F has the edge over MED on earnings, with more consistent year-over-year improvement.
MED Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.68 | -18500% |
| Q2 2026 | -$2.32 | -803% |
| Q1 2026 | -$1.82 | -$1.18 |
| Q4 2025 | -$1.70 | -995% |
| Q3 2025 | $0.02 | -97% |
| Q2 2025 | $0.33 | -88% |
| Q1 2025 | -$0.64 | -110% |
| Q4 2024 | $0.19 | -98% |
MED has swung to a loss: it lost $3.68 per share over the past year, after a profit the year before.
F Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $49.5B | -2% |
| Q2 2026 | $48.3B | -3.8% |
| Q1 2026 | $43.3B | +6.4% |
| Q4 2025 | $45.9B | -4.8% |
| Q3 2025 | $50.5B | +9.4% |
| Q2 2025 | $50.2B | +5% |
| Q1 2025 | $40.7B | -5% |
| Q4 2024 | $48.2B | +4.9% |
F has the edge over MED on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.9% | -0.1 points |
| Q2 2026 | 1.3% | +0.3 points |
| Q1 2026 | 5.4% | +4.6 points |
| Q4 2025 | -25% | -28 points |
| Q3 2025 | 3.1% | +1.2 points |
| Q2 2025 | 1% | -2.9 points |
| Q1 2025 | 0.8% | -2.1 points |
| Q4 2024 | 2.5% | +3.1 points |
F has the edge over MED on profitability, with a higher operating margin.
MED Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $72M | -19% |
| Q2 2026 | $76.4M | -28% |
| Q1 2026 | $76M | -34% |
| Q4 2025 | $75.1M | -37% |
| Q3 2025 | $89.4M | -36% |
| Q2 2025 | $105.6M | -37% |
| Q1 2025 | $115.7M | -34% |
| Q4 2024 | $119M | -38% |
MED's revenue has slid since its 2022 peak: $72M last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -27% | -22 points |
| Q2 2026 | -5.7% | -4.7 points |
| Q1 2026 | -4.3% | -3.2 points |
| Q4 2025 | -10% | -11 points |
| Q3 2025 | -4.6% | -6.1 points |
| Q2 2025 | -1% | +3.7 points |
| Q1 2025 | -1.1% | -5.6 points |
| Q4 2024 | 0.6% | -3.9 points |
MED's operating margin was −27% last quarter, down 22 points from the same quarter a year ago, near the bottom of its range since 2019.
F Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.1B | -40% |
| Q2 2026 | $2B | -54% |
| Q1 2026 | -$1.1B | -157% |
| Q4 2025 | $1.1B | +108% |
| Q3 2025 | $5.3B | +50% |
| Q2 2025 | $4.2B | +24% |
| Q1 2025 | $1.9B | +$2.6B |
| Q4 2024 | $530M | +169% |
F has the edge over MED on cash generation, producing positive trailing cash flow while its opponent burns cash.
MED Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.9M | -73% |
| Q2 2026 | $728K | +$5.5M |
| Q1 2026 | -$836K | -144% |
| Q4 2025 | -$6.6M | +$603K |
| Q3 2025 | $10.8M | +40% |
| Q2 2025 | -$4.8M | -143% |
| Q1 2025 | $1.9M | -65% |
| Q4 2024 | -$7.2M | -176% |
MED's free cash flow has turned negative after years in the green: −$4M over the past year.
F Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.2% | +89M shares |
| 1 year | +0.7% | +28M shares |
| 3 years | +0.6% | +26M shares |
| 5 years | +1% | +40M shares |
| Available history | +1.8% | +72M shares |
F has the edge over MED on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $311M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $150M |
F spent $311M buying back its own shares over the past year, up 107% from the year before.
MED Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +46K shares |
| 1 year | +1.7% | +190K shares |
| 3 years | +2.3% | +248K shares |
| 5 years | -5.1% | -604K shares |
| Available history | -7.7% | -936K shares |
MED has 11M diluted shares, up 1.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | $3.6M |
F Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.5x | Net Cash |
| Q2 2026 | -2.1x | Net Cash |
| Q1 2026 | -2.0x | Net Cash |
| Q4 2025 | -3.4x | Net Cash |
| Q3 2025 | -2.4x | Net Cash |
| Q2 2025 | -2.2x | Net Cash |
| Q1 2025 | -1.8x | Net Cash |
| Q4 2024 | -1.8x | Net Cash |
F has more cash than debt.
MED Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -2,976.8x | Net Cash |
| Q3 2025 | -12.1x | Net Cash |
| Q2 2025 | -7.2x | Net Cash |
| Q1 2025 | -14.3x | Net Cash |
| Q4 2024 | -5.8x | Net Cash |
| Q3 2024 | -4.9x | Net Cash |
| Q2 2024 | -2.3x | Net Cash |
| Q1 2024 | -1.0x | Net Cash |
MED has more cash than debt.
F Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.5 | Neutral |
| Stochastic | 19.6 | Oversold |
F's weekly RSI is 41 (neutral) and its Stochastic is 20 (oversold).
MED Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.1 | Neutral |
| Stochastic | 72.6 | Neutral |
MED's weekly RSI is 59 (neutral) and its Stochastic is 73 (neutral).
F PE vs Consumer Cyclical Sector
| Metric | F | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
F has no meaningful PE right now: it lost money over the past year.
MED PE vs Consumer Cyclical Sector
| Metric | MED | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
MED has no meaningful PE right now: it lost money over the past year.
F Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.2 | 2.5% below |
| 20 week MA | $13.3 | 11% below |
| 50 week MA | $13.4 | 11% below |
| 100 week MA | $12.1 | 2% below |
| 200 week MA | $12.1 | 1.4% below |
F is in a downtrend: it's below all five of its weekly moving averages, and 1.4% below its 200-week average.
MED Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.1 | 6% above |
| 20 week MA | $11.7 | 10% above |
| 50 week MA | $11.4 | 13% above |
| 100 week MA | $12.6 | 1.9% above |
| 200 week MA | $35.4 | 64% below |
MED has the edge over F on trend strength, trading above more of its moving averages.
F Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.36 | $8.86 | -5.3% |
| 2021 | $8.86 | $20.3 | +129% |
| 2022 | $20.3 | $11.4 | -44% |
| 2023 | $11.4 | $12.2 | +7.3% |
| 2024 | $12.2 | $10.0 | -18% |
| 2025 | $10.0 | $13.3 | +33% |
| 2026 YTD | $13.3 | $11.9 | -11% |
F's yearly returns have swung widely, from +129% in 2021 to −44% in 2022. It's down 11% so far in 2026.
MED Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $108.3 | $196.7 | +82% |
| 2021 | $196.7 | $204.2 | +3.8% |
| 2022 | $204.2 | $117.1 | -43% |
| 2023 | $117.1 | $67.2 | -43% |
| 2024 | $67.2 | $17.6 | -74% |
| 2025 | $17.6 | $11.0 | -37% |
| 2026 YTD | $11.0 | $12.9 | +16% |
MED has the edge over F on returns for 2026, with the stronger performance.